Ticagrelor is an antiplatelet medication that is used to reduce the rate of cardiovascular events, including death. It belongs to a class of drugs called cyclooxygenase (COX)-2 inhibitors. It works by reducing the production of thromboxane A2 (TXA2), a platelet-activating molecule that can lead to clot formation. Ticagrelor is used in most countries to reduce the risk of stroke and heart attack in people with established or at high risk of cardiovascular disease.
Ticagrelor is used to reduce the risk of death or stroke in patients with acute coronary syndrome (ACS). It is also recommended for those with acute ischemic stroke in some countries, and for reducing the risk of peripheral arterial disease in patients with coronary artery disease. It is also sometimes used to reduce angina in some patients.
| Brand Name | Ticagrelor |
|---|---|
| Type | |
| Weight | |
| Generic | Ticagrelor |
| Manufacturer | |
| Available in | English বাংলা |
Ticagrelor works by blocking the action of the enzyme cyclooxygenase-2 (COX-2), which is responsible for the production of thromboxane A2 (TXA2), a platelet-activating molecule. By blocking TXA2, ticagrelor reduces the chances of clot formation. It also helps to keep platelets from sticking to each other, which prevents them from clumping together and creating clots. This helps to reduce the risk of stroke and heart attack.
Ticagrelor generally takes effect within 10 minutes after it is taken. The effects lasts for about a day, until the body has processed and eliminated the medication.
Ticagrelor is rapidly and almost completely absorbed after oral administration. The maximum concentration is usually reached within 1–2 hours.
Ticagrelor is mainly eliminated through the kidneys. It is excreted in the urine as unchanged drug and metabolites.
The recommended adult dosage for ticagrelor is 60 mg twice daily. It should be taken with food to reduce the risk of stomach and intestine irritation. It is not recommended for patients with severe renal impairment.
Ticagrelor is usually taken by mouth, as a tablet or an oral suspension. It is recommended to be taken with food. It should be taken exactly as prescribed by the doctor.
Common side effects of ticagrelor include headache, indigestion, nausea, vomiting, diarrhea, dizziness, fatigue, and rash. Rare side effects can include bleeding complications, hypotension, and liver problems.
Ticagrelor is safe when used as recommended. The most serious effect of overdose is bleeding. Seek medical attention immediately if you suspect an overdose.
Ticagrelor should be used with caution in patients with a history of bleeding disorders or who take other medications that increase the risk of bleeding. It is also not recommended for pregnant women and those who are breastfeeding.
Ticagrelor may interact with certain drugs, including anticoagulants, antiplatelet drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs). It is important to tell your doctor about all medications and supplements, including vitamins and herbal products, you are taking before taking ticagrelor.
Ticagrelor may interact with diseases such as liver disease, kidney disease, and bleeding disorders. Tell your doctor about any medical conditions you may have before taking ticagrelor.
Ticagrelor may interact with other medications, including anticoagulants, antiplatelet drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs). Tell your doctor about all medications and supplements, including vitamins and herbal products, you are taking before taking ticagrelor.
Food does not significantly affect the absorption of ticagrelor, but it is recommended to take the medication with food to reduce the risk of stomach and intestine irritation.
Ticagrelor is not recommended for use during pregnancy. It has the potential to cause serious harm to a developing fetus.
Ticagrelor is excreted in breast milk and is not recommended for use while breastfeeding. It may cause serious harm to a nursing baby.
If an overdose is suspected, seek medical attention immediately. The most serious effect of overdose is bleeding.
Ticagrelor is contraindicated in patients with a history of severe renal impairment, a history of bleeding disorders, during pregnancy and breastfeeding, and in patients taking other medications that increase the risk of bleeding.
Ticagrelor should be taken exactly as prescribed by the doctor. It is usually taken orally, as a tablet or an oral suspension with food. It is not recommended for use in patients with severe renal impairment.
Ticagrelor should be stored at room temperature away from direct sunlight and heat. Keep it in a dry place and out of reach of children.
The volume of distribution of ticagrelor in humans is approximately 176 L, indicating widespread distribution of the drug throughout the body.
The half-life of ticagrelor is approximately 8 hours. After 24 hours, the drug has been largely eliminated from the body.
The clearance of ticagrelor is approximately 21 L/h, indicating that it is quickly cleared from the body. It is mainly eliminated through the kidneys as unchanged drug and metabolites.
See in details version Ticagrelor also Ticagrelor in bangla
Ticagrelor is an antiplatelet medication used to prevent blood clots in patients with acute coronary syndrome (ACS) or those who have undergone procedures like angioplasty. It reduces the risk of heart attacks and strokes by preventing platelets from sticking together.
Ticagrelor works by blocking the P2Y12 receptor on platelets, preventing them from clumping together and forming clots. This reduces the risk of heart attacks, strokes, and other cardiovascular events.
Ticagrelor is mainly used to treat:
Yes, Ticagrelor is classified as an antiplatelet drug, which acts as a blood thinner to prevent clot formation. However, it works differently from anticoagulants like warfarin or heparin.
Ticagrelor is usually taken orally, twice a day, with or without food. It is often prescribed alongside low-dose aspirin (75-100 mg daily) for maximum effectiveness.
The standard dose of Ticagrelor is a 180 mg loading dose, followed by 90 mg twice daily for the first 12 months. After 12 months, the dose may be reduced to 60 mg twice daily.
Yes, Ticagrelor is usually prescribed with a low dose of aspirin. However, high-dose aspirin (greater than 100 mg daily) may reduce the effectiveness of Ticagrelor .
Common side effects include:
Yes, since Ticagrelor prevents blood clotting, it increases the risk of bleeding. Patients may experience bruising, nosebleeds, or prolonged bleeding from minor cuts.
If you miss a dose, take it as soon as you remember. However, if it’s almost time for your next dose, skip the missed dose and return to your regular schedule. Do not double up to make up for a missed dose.
Ticagrelor is generally not recommended during pregnancy unless the potential benefits outweigh the risks. Consult your healthcare provider if you are pregnant or planning to become pregnant.
It is not known if Ticagrelor passes into breast milk. Breastfeeding mothers should consult a doctor before using this medication.
Patients are typically advised to take Ticagrelor for at least 12 months after a heart attack or stent placement. In some cases, it may be continued for longer if recommended by a healthcare provider.
Ticagrelor may interact with certain medications, including:
Yes, Ticagrelor is often prescribed to elderly patients. However, they may have an increased risk of bleeding and should be closely monitored during treatment.
Ticagrelor is not recommended for patients with severe liver disease. Liver function should be assessed before starting the medication.
Yes, some patients experience shortness of breath (dyspnea) while taking Ticagrelor . This side effect is usually mild and temporary, but it should be reported to a doctor if severe.
Although rare, some individuals may experience allergic reactions like rash, itching, or swelling. Seek immediate medical help if you experience signs of a severe allergic reaction.
Yes, Ticagrelor is used to reduce the risk of stroke in patients with a history of heart disease, coronary artery disease (CAD), or previous stroke events.
No, stopping Ticagrelor suddenly without medical advice can increase the risk of heart attack or stroke. Always follow your doctor’s instructions when discontinuing the medication.
If you suspect a Ticagrelor overdose, seek emergency medical attention. Symptoms may include severe bleeding or difficulty breathing.
Ticagrelor is generally safe for people with mild or moderate kidney disease. However, kidney function should be monitored, particularly in patients with severe kidney impairment.
Routine monitoring is not usually required for Ticagrelor , but doctors may perform periodic blood tests to assess bleeding risk or liver function.
If you need surgery, inform your surgeon that you are taking Ticagrelor . It may need to be stopped temporarily before major surgery to reduce bleeding risk.
In most cases, Ticagrelor is prescribed for 12 months, but some patients may need to continue it long-term to prevent future cardiovascular events. Your doctor will decide the duration based on your health condition.
Dr. Md. Ali Faisal Liton
Orthopedics, Arthroscopy & Arthroplasty Surgeon
Orthopedics Doctor in Dhaka
Dr. Md. Manir Hossain Khan
General, Laparoscopic, Hepatobiliary, Colorectal & GI Surgeon
General Surgeon in Dhaka